Medication Reconciliation in Hospitalized CKD Patients : A Quasi-Experimental Study

January 27, 2026 updated by: Jordan University of Science and Technology

The Impact of Medication Reconciliation on Discrepancies and All-cause Readmission Among Hospitalized Patients With Chronic Kidney Disease: A Quasi-experimental Study

This study aimed to evaluate the impact of combining medication reconciliation with medication review on reducing medication discrepancies at discharge and all-cause readmissions among CKD patients, in comparison to a retrospective control group that received usual care, which may or may not have included medication reconciliation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

323

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Jordan
      • Irbid, Jordan, 22110
        • King Abdullah University Hospital and Princess Basma Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult (18 years or older) admitted patients with CKD (stages 2-5 ), who were using at least three chronic medicines at home, and were hospitalized for at least 48 hours.

Exclusion Criteria:

  • Patients with kidney transplantation .
  • Patients who have difficulties in responding to interviews and did not have family member or caregiver on behave.
  • Patients who refused to provide a written informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
interventional group, in which patients received a supplemented medication reconciliation service.
Other: Medication reconciliation service
Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.
No Intervention: Retrospective control group in which patients received the usual care
A retrospective control group in which patients received the usual care that may or may not include medication reconciliation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
all-cause 90-day readmission
Time Frame: 90 days after discharge
The primary outcome in this study was the likelihood of all-cause 90-day readmission as extracted from medical records for both study groups
90 days after discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jordan University of Science and Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2023

Primary Completion (Actual)

August 30, 2023

Study Completion (Actual)

August 30, 2023

Study Registration Dates

First Submitted

February 5, 2025

First Submitted That Met QC Criteria

February 5, 2025

First Posted (Actual)

February 11, 2025

Study Record Updates

Last Update Posted (Actual)

January 29, 2026

Last Update Submitted That Met QC Criteria

January 27, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Grant number: 20220257

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe